Despite several big pharmas leaving neurology, the drug pipeline is the second largest after oncology. The FDA approved Hemacord, the first off-the-shelf human cord blood cell product. Positive efficacy was also obtained for cell therapies in congestive heart failure (MyoCell) and limb ischemia (Imyelocel-T). Panaclar and ocrelizumab met their end points in multiple sclerosis as did DiaPep277 in type I diabetes. The oncolytic treatment Reolysin showed positive phase 2 results in head and neck cancer. On the downside, Sangamo Biosciences' lead zinc-finger program was discontinued.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mak, H. Drug pipeline: Q411. Nat Biotechnol 30, 15 (2012). https://doi.org/10.1038/nbt.2090
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2090
